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To assess whether after the introduction of diabetes performance measures
decreases in undertreatment correspond with increases in overtreatment for
blood pressure (BP) and glycemic control in different patient age groups.
RESEARCH DESIGN AND METHODS
We conducted a cohort study using data from the Groningen Initiative to Analyse
Type 2 Diabetes Treatment (GIANTT) database. General practices were included
when datawere available from 1 year before to at least 1 year after the introduction
of diabetes performance measures. Included patients had a confirmed diagnosis of
type 2 diabetes. Potential overtreatment was defined as prescribing maximum
treatment or a treatment intensification to patients with a sustained low-risk factor
level. Potential undertreatment was defined as a lack of treatment intensification
in patients with a sustained high-risk factor level. Percentages of over- and under-
treated patients at baseline were compared with those in subsequent years, and
stratified analyses were performed for different patient age groups.
RESULTS
For BP, undertreatment significantly decreased from 61 to 57% in the first year
after the introduction of performance measures. In patients >75 years of age,
undertreatment decreased from 65 to∼61%. Overtreatment was relatively stable
(∼16%). For glycemic control, undertreatment significantly increased from 49 to
53%, and overtreatment remained relatively stable (∼7%).
CONCLUSIONS
The improvement of BP undertreatment after introduction of the performance
measures did not correspondwith an increase in overtreatment. The performance
measures appeared to have little impact on improving glucose-regulating treat-
ment. The trends did not differ among patient age groups.
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The quality of diabetes care, and in
particular potential undertreatment
of cardiometabolic risk factors, has
received much attention in the past
decade. Several improvements have
been observed in the process as well
as the outcomes of the care for
patients with type 2 diabetes (1–3).
These improvements have been
stimulated by quality assurance and
pay-for-performance programs,
which incorporate performance
measurements focusing on achieving
risk factor targets (4–6).
In clinical guidelines for diabetes
management (DM), the general target
for glycohemoglobin (HbA1c) con-
centration is set at,7% (53 mmol/mol)
and for systolic blood pressure (SBP)
at ,140 mmHg or even ,130 mmHg
for some patients (7,8). However, the
debate about the target levels being
too strict has intensified, in particular
with regard to the aged patients
(9–12). In addition, concerns have
been raised that the introduction of
performance measures may stimulate
potential overtreatment since provid-
ers are rewarded with financial incen-
tives for achieving strict targets (9,13).
Recently, Kerr et al. (14) reported that
among veterans with diabetes, poten-
tial overtreatment for BP was ap-
proaching that of undertreatment.
These findings may not be unique for
BP treatment, and similar trends may
be expected for glucose-regulating
treatment.
One may expect that the influence of
performance measures will differ in
different settings as well as among
general practices (GPs) (15).
Performance rates and the extent of
potential overtreatment may vary
among practitioners and facilities
(14,16), and changing this performance
is a complex process that is influenced
by multiple factors (17). Kerr et al. (14)
found that facilities with low levels of
undertreatment were more likely to
have higher levels of overtreatment.
Our aim was to assess whether, after the
introduction of performance measures in
the Netherlands, decreases in potential
undertreatment for BP and glycemic
control correspond with increases in
potential overtreatment in patients with
type 2 diabetes. In addition, we assessed
whether under- and overtreatment differ
for different patient age groups.
RESEARCH DESIGN AND METHODS
Study Design
We conducted an observational,
dynamic cohort study from 2007–2011
of patients with type 2 diabetes in GPs in
the province of Groningen in the
Netherlands. The GPs are all member
of a diabetes care group (DCG). Such
DCGs, comparable with accountable care
organizations in the U.S., were formed
after the introduction of bundled
payment in 2007 in the Netherlands (18).
The DCGs are responsible for the
organization and provision of diabetes
care in accordance with the Dutch
Diabetes Federation Health Care Standard
(19). Diabetes performance measures
were instituted in this region from 2008
onward as part of this program. GPs
received yearly feedback comparing
their own practice performance with
performance measures of the whole
region and with benchmarks set by the
DCG. There were no personal incentives
or penalties linked to this benchmarking.
GPs entered the DM program at different
time points (Fig. 1) (20–24).
Study Population and Data Collection
Data were collected from the Groningen
Initiative to Analyse Type 2 Diabetes
Treatment (GIANTT) database including
almost all regional patients with type 2
diabetes (,1% opted out). The cohort of
patients was based on the GPs of which
data were available for 1 year before up
to at least 1 year after entry in the DM
program.
Based on the GPs’ entry date in the DM
program, the following cohort years
were created: year before entry
(baseline year), year of entry, 1 year
after entry, and, if available, 2 and 3
Figure 1—Time flow of study with key publications and national guidelines relevant for the treatment of (elderly) patients with high BP or HbA1c
levels. ACCORD, Action to Control Cardiovascular Risk in Diabetes; ADVANCE, Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR
Controlled Evaluation; HYVET, Hypertension in the Very Elderly Trial.
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years after entry. For practices
entering in the second half of a
calendar year, the next year was used
as year of entry.
Per cohort year, patients were included
who had a confirmed diagnosis of type 2
diabetes before January 1. Routinely
collected data of the patients, including
full prescription data, laboratory test
results, and physical examinations, were
extracted from electronic medical
records using validated procedures (25).
In the Netherlands, no approval from an
ethics committee is needed for studies
using data from anonymous medical
records.
Outcome Measures
Primary outcome measures were
potential over- and undertreatment.
The definitions of potential overtreatment
were based on those suggested by Kerr
et al. (14) and validated by assessing the
association between overtreatment
and experiencing an adverse drug
event. The definitions of potential
undertreatment were derived from
practice guidelines (7,14,26–28). We
defined separate definitions for BP- and
glucose-lowering treatment. The first
measurement of SBP or HbA1c in a year
was taken as index date. Treatment
status and changes in treatment were
assessed relative to this index
measurement.
Potential overtreatment was defined as:
c SBP ,130 mmHg and receiving $3
BP-lowering drugs or an increase in
dose within 120 days after the index
date or a start of a new BP-lowering
drug class within 120 days after the
index date and without next SBP
measurement $130 mmHg within
120 days after the index date.
c HbA1c ,6.5% (48 mmol/mol) and
receiving $3 glucose-lowering drugs
or insulin or an increase in dosewithin
120 days after the index date or a
start of a new glucose-lowering
drug class within 120 days after the
index date and without next HbA1c
measurement $6.5% (48 mmol/mol)
within 120 days after the index date.
Potential undertreatmentwas defined as:
c SBP$140 mmHg and not on$ 3 BP-
lowering drugs without any increase
in dose within 120 days after the
index date, start of a new BP-lowering
drug class within 120 days after the
index date, or switch to another BP-
lowering drug class within 120 days
after the index date and without next
SBP measurement ,140 mmHg in
the up to 120 days after the index
date.
c HbA1c $7% (53 mmol/mol) and (not
on $3 glucose-lowering drugs or
insulin without any increase in dose
within 120 days after the index date,
start of a new glucose-lowering drug
class within 120 days after the index
date, or switch to another glucose-
lowering drug class within 120 days
after the index date and without
next HbA1c measurement ,7% (53
mmol/mol) in the period up to
120 days after the index date.
We used a period of 120 days to assess
changes in treatment after the index
date to capture clinical actions that
were postponed to the next regular
visit, which is commonly after 3 months
in the Netherlands (28,29). The
therapeutic groups of BP- and glucose-
lowering treatment included seven
and eight drug classes, respectively
(Table 1). The start of a drug was
defined as a new drug prescription for a
drug that had not been prescribed in
270 days before the start of the first
prescription after the index date. A stop
was defined as no repeat prescription
within 270 days after the start date of
the last prescription. Stops before 7
days after index date were not
considered as stops related to the
measurement at index date. When a
drug class was started within 7 days
after the stop date of another drug
class, the stop was considered a switch.
The following combined changes were
considered as no change when
assessing over- or undertreatment: a
dose decrease combined with a dose
increase, addition of a drug class
combined with a dose decrease, and
stop of a drug combined with a dose
increase.
Table 1—Characteristics of GPs and patients in the year of entry in the DM program
GPs (N) 133
Median number of patients with type 2 diabetes per GP (IQR) 117 (91–162)
Total number of patients with type 2 diabetes 14,876
Female patients (%) 7,674 (51.6)
Mean age of patients in years at index date SBP (SD) 66.8 (12.2)
Median diabetes duration at SBP measurement (IQR) 5 (2–9)
Number of patients without prescription of BP-lowering drug in
6 months up to index date 3,077 (23.8)
Drug classes of BP-lowering drugs (%)*
ACE inhibitors 5,117 (39.6)
Angiotensin II antagonists 2,673 (20.7)
Drugs acting on the renin–angiotensin system 4 (0.0)
Diuretics 5,854 (45.3)
b-Blockers 5,133 (39.7)
Calcium channel blockers 2,679 (20.7)
Centrally acting antihypertensives 235 (1.8)
Number of patients without prescription for glucose-lowering
drug in 6 months up to index date 2,525 (18.6)




a-Glucosidase inhibitors 14 (0.1)
Thiazolidinediones 588 (4.3)
Dipeptidyl peptidase 4 inhibitors 92 (0.7)
Repaglinide 5 (0.0)
Exenatide or liraglutide 6 (0.0)
IQR, interquartile range. *Number of patients who have been prescribed the drug class in the
6 months up to index date.
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Analysis
Characteristics of the patient population
were assessed for the year of entry to
the DM program. Age and diabetes
duration of the patients were calculated
on the index date. For patients without
an index date, the average index date of
the other patients was used to assess
their age and diabetes duration. The
validation of the definition of potential
overtreatment was performed using x2
statistics.
Percentages of potential over- and
undertreatment to BP- and glucose-
lowering treatment were assessed in all
patients and in eligible patients only.
Eligible patients for overtreatment are
patients with low-risk factor levels
without an apparent need for
intensified treatment, whereas eligible
patients for undertreatment include
those with high-risk factor levels,
who are not on maximum treatment,
and in whom additional treatment is
usually indicated. Maximum treatment
was defined as a prescription of three
or more drug classes or insulin (only
for the glucose-lowering drugs) in 6
months before and up to the index
date.
Percentages of over- and
undertreatment in the baseline year
were compared with those in the
subsequent years using z-approximation
for differences between proportions.
Subsequently, stratified analyses
were conducted for the age groups
,60, 60–75, and .75 years (3).
Sensitivity analyses were conducted
using more relaxed definitions for
overtreatmentdthat is, including only
patients with levels of SBP,120 mmHg
and HbA1c ,6% (42 mmol/mol) as
eligible for overtreatment.
The influence of the introduction of
diabetes performance levels at GP
level was assessed by comparing the
percentages of over- and undertreated
patients at baseline with 1 year after
entry. GPs were divided into three
groups, namely those with a $5%
increase, $5% decrease, or stable
percentage of patients with over- or
undertreatment between the two
measurements. We used x2 statistics
to test for associations between
changes in over- and undertreatment
at the GP level.
The analyses were conducted using
Stata version 12 (Stata Corp., College
Station, TX), and P values ,0.05 were
considered statistically significant.
RESULTS
In total, 133 GPs entered the DM
program: 32 in the cohort of 2008, 65 in
2009, and 36 in 2010. This resulted in
133 GPs with follow-up data of at least
1 year, 97 GPs with follow-up data of
2 years, and 32 GPs with follow-up data
of 3 years after entering the program
(Fig. 1). The patient population at year
of entry consisted of 14,876 patients
with a mean age of 67 years and 52%
females (Table 1). Of the BP-lowering
drugs, the diuretics were the most
commonly prescribed drug class (45%),
followed by the b-blockers (40%) and
the ACE inhibitors (40%). Metformin
(64%) and sulfonylurea derivatives
(40%) were the most commonly
prescribed glucose-lowering drugs.
Potential overtreatment was associated
with more possible adverse events
related to the specific drug classes of BP-
and glucose-lowering treatment
(Supplemental Table 1).
For all patients with SBPmeasurements,
potential overtreatment was observed
in 3.2–3.8% in the study period,
whereas potential undertreatment
was seen in 18.6–25.4%. For all
patients with HbA1c measurements,
potential overtreatment was seen in
2.0–2.4% and undertreatment in
14.8–16.5%.
BP-Lowering Treatment
Potential overtreatment among eligible
patients with an SBP ,130 mmHg
was 15.9% at baseline and remained
relatively stable in the years after entry
to the DM program (P. 0.05) (Table 2).
This pattern was similar for the different
patient age groups (Fig. 2). Potential
overtreatment mainly involved patients
receiving maximum treatment of BP-
lowering drugs (;14% of eligible
patients), which was generally more
common in patients .75 years of age
(data not shown). Intensification of
treatment occurred in;3%of the eligible
patients (Table 2) and was comparable
among the patient age groups (data not
shown). Similar nonsignificant patterns
of overtreatment were found in patients
with an SBP ,120 mmHg, being the
more relaxed definition of
overtreatment (Supplemental Table 2).
Potential undertreatment of eligible
patients with an SBP $140 mmHg was
extensive but decreased from 60.7% in
the baseline year to 56.9–50.7% in the
years after entry (Table 2). The
percentages were significantly (P ,
0.05) different for all 3 years after entry
in the DM program in comparison with
the baseline year and were largely due
to the improvements in patients aged
#75 years (Fig. 2). In patients.75 years
of age, undertreatment decreased from
64.7% to;61% in the years after entry.
In general, potential undertreatment of
BP treatment was more common in
elderly patients.
Glucose-Lowering Treatment
Potential overtreatment among eligible
patients with an HbA1c ,6.5% (48
mmol/mol) was observed in 7.4% of the
patients at baseline (Table 2). This
percentage did not significantly change
in the years after entry in the DM
program. In patients ,60 years of age,
overtreatment was 6.7% at baseline,
which increased to 7.5–10.3% in the
years after entry (Fig. 2). The percentage
of patients with an HbA1c ,6.5% (48
mmol/mol) receiving intensification of
glucose-lowering treatment was
significantly higher in later years (1.9% in
the baseline year and ;3% in the years
after entry). However, the percentage
of patients receiving maximum
treatment decreased significantly in
later years (1.2% in the baseline year
and 0.3–0.6% in the years after entry;
Table 2). The increase in intensification
over time was particularly seen in
patients ,60 years of age, whereas the
decrease in receiving maximum
treatment was seen in all patient age
groups. Insulin use was generally more
common in patients .75 years of age
(data not shown). The pattern of
overtreatment was similar for patients
with the more relaxed definition of,6%
(42 mmol/mol) for HbA1c (Supplemental
Table 2).
Potential undertreatment of patients
with an HbA1c $7% (53 mmol/mol)
increased from 49.2% at baseline to
53.0% in the first year after entry (Table
2). The percentages were significantly
higher in all 3 years after entry in the DM
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program compared with the baseline
year. This increase was largest in the
second year after entry, a pattern
that was observed in all three age
groups (Fig. 2). Overall, potential
undertreatment for glycemic control
was more common in elderly patients.
GP Level
A decrease in undertreatment for SBP
was seen for 44% (N = 57) of the GPs,
while for only 29% (N = 38) an increase
in overtreatment for SBP was seen. Of
the 57 GPs that showed a decrease in
undertreatment, 26 also showed
a decrease in overtreatment (46%),
whereas only 20 (35%) showed an
increase in overtreatment. This
association between improvements in
under- and overtreatment at the GP
level for SBP was statistically significant
(P = 0.02; Supplemental Table 3). For
HbA1c, 25% of the GPs had a decrease in
undertreatment, and the same number
had an increase in overtreatment. No
significant associations were seen
between changes in under- and
overtreatment at the GP level for HbA1c
(P = 0.13; Supplemental Table 3).
CONCLUSIONS
During the entire period from 2007–
2011, potential overtreatment was
much less common than potential
undertreatment for both BP and glycemic
control. Following the introduction of
Table 2—Numbers of potential overtreatment and undertreatment for patients with SBP or HbA1c measurements








With SBP measurement (% of all patients) 11,517 (84.4) 12,927 (86.9) 14,579 (89.8) 11,702 (91.2) 4,573 (94.2)
Mean age in years (SD) 67.1 (12.0) 67.0 (12.0) 67.0 (11.9) 67.0 (12.0) 67.1 (11.5)
Percent females 52.9 51.9 51.6 51.9 50.8
Median DM duration (IQR) 4 (2–8) 5 (2–9) 5 (2–9) 5 (2–9) 5 (2–9)
Mean SBP (SD) 144.0 (20.4) 144.7 (20.6) 144.2 (20.0) 142.7 (19.4) 142.6 (19.2)
N SBP ,130 mmHg 2,451 2,618 2,969 2,542 1,000
N SBP,130mmHg with potential overtreatment (% of
eligible patients) 389 (15.9) 413 (15.8) 472 (15.9) 443 (17.4) 162 (16.2)
N classes $3† 331 (13.5) 366 (14.0) 408 (13.7) 381 (15.0) 136 (13.6)
N intensified† 82 (3.3) 69 (2.6) 87 (2.9) 81 (3.2) 36 (3.6)
Glucose-lowering overtreatment
With HbA1c measurement (% of all patients) 12,117 (88.8) 13,548 (91.1) 14,999 (92.4) 11,884 (92.6) 4,499 (92.7)
Mean age in years (SD) 66.9 (12.0) 66.9 (12.0) 66.9 (12.0) 66.9 (12.0) 67.0 (11.6)
Percent females 52.8 51.8 51.6 51.7 50.6
Median DM duration (IQR) 4 (2–8) 5 (2–9) 5 (2–9) 5 (2–9) 5 (2–9)
Mean HbA1c (SD) 6.9 (1.0) 7.0 (1.0) 7.0 (1.0) 7.0 (1.0) 7.0 (0.9)
N HbA1c ,6.5% (48 mmol/mol) 3,980 4,150 4,510 3,518 1,209
N HbA1c ,6.5% (48 mmol/mol) with potential
overtreatment (% of eligible patients) 296 (7.4) 310 (7.5) 341 (7.6) 239 (6.8) 103 (8.5)
N classes $3† 46 (1.2) 28 (0.7)* 25 (0.6)* 20 (0.6)* 4 (0.3)*
N insulin use† 178 (4.5) 181 (4.4) 193 (4.3) 126 (3.6) 58 (4.8)
N intensified† 77 (1.9) 102 (2.5) 130 (2.9)* 100 (2.8)* 45 (3.7)*
BP-lowering undertreatment
With SBP measurement and not on maximum treatment
(% of all patients) 8,387 (61.5) 9,250 (62.2) 10,373 (63.9) 8,246 (64.3) 3,178 (65.5)
Mean age in years (SD) 65.9 (12.3) 65.8 (12.4) 65.6 (12.2) 65.6 (12.3) 65.6 (11.7)
Percent females 51.6 50.8 50.4 50.9 49.8
Median DM duration (IQR) 4 (2–8) 4 (2–8) 4 (2–8) 5 (2–8) 5 (2–9)
Mean SBP (SD) 142.7 (19.6) 143.5 (19.7) 142.9 (19.1) 141.3 (18.5) 141.0 (18.2)
N with SBP $140 mmHg not on maximum treatment 4,826 5,449 5,924 4,430 1,676
N with SBP $140 mmHg not on maximum treatment
with potential undertreatment (% of eligible patients) 2,931 (60.7) 3,209 (58.9) 3,370 (56.9)* 2,466 (55.7)* 850 (50.7)*
Glucose-lowering undertreatment
With HbA1c measurement and not on maximum
treatment (% of all patients) 10,219 (74.9) 11,413 (76.7) 12,593 (77.6) 9,969 (77.7) 3,712 (76.5)
Mean age in years (SD) 66.7 (12.0) 66.7 (12.0) 66.7 (11.9) 66.7 (11.9) 66.8 (11.5)
Percent females 51.9 50.8 51.0 51.2 50.6
Median DM duration (IQR) 4 (2–7) 4 (2–8) 4 (2–8) 4 (2–8) 4 (2–8)
Mean HbA1c (SD) 6.8 (1.0) 6.9 (0.9) 6.8 (0.9) 6.8 (0.9) 6.9 (0.9)
NHbA1c$7% (53mmol/mol) not onmaximumtreatment 3,652 4,187 4,405 3,479 1,368
NHbA1c$7% (53mmol/mol) not onmaximumtreatment
with potential undertreatment (% of eligible patients) 1,796 (49.2) 2,145 (51.2) 2,335 (53.0)* 1,962 (56.4)* 725 (53.0)*
Baseline is the year before entry in the DMprogram. Follow-up year 1 is 1 year after entry, follow-up year 2 is 2 years after entry, and follow-up year 3
is 3 years after entry. IQR, interquartile range. *Percentages of overtreatment or undertreatment in years of participation in the DM program that
significantly differ from the baseline year (P, 0.05). †Percentages do not sum to the percentages of patients with potential overtreatment because
patients can be included in multiple categories of overtreatment.
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diabetes performance measures, in the
period 2008–2010, therewas a significant
decrease in potential undertreatment
and a relatively stable level of potential
overtreatment for BP. For HbA1c, we
observed a relatively stable level of
overtreatment and an unexpected
increase in potential undertreatment
after the introduction of performance
measures. These results hardly differed
among the patient age groups, although
levels of potential undertreatment for
both BP and HbA1c were generally higher
in aged patients.
There can be good reasons to deviate
from guideline recommendations for
individual patients. Regarding
overtreatment, there are currently no
minimum levels for BP or HbA1c, and
measures of overtreatment have been
criticized (30). We used the same cutoff
Figure 2—Trends in percentages of over- and undertreated patients based on eligible patients and P values of the comparison of baseline year with
subsequent years. Baseline, year before entry to the DM program; Entry DM program, entry to DM program; Follow-up year 1, 1 year after entry;
Follow-up year 2, 2 years after entry; Follow-up year 3, 3 years after entry. *Percentages of overtreatment or undertreatment in years of
participation in the DM program that significantly (P , 0.05) differ from the baseline year (reference year). Ref., reference.
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levels of overtreatment for all patient
age groups, since the prevailing
guidelines during the study period did
not distinguish different target levels
across age groups. Using different levels
for defining potential overtreatment,
we found similar results. We observed a
decrease in the percentages of patients
on maximum treatment. However, we
also observed a small increase over time
in treatment intensification rates in
patients already having low HbA1c
levels. This finding was particularly seen
in younger patients, which implies that
GPs need to be more cautious with
intensifying treatment in this specific
patient group. Potential overtreatment
was more common in BP-lowering
treatment than in glucose-lowering
treatment. However, the need for
additional treatment with BP-lowering
drugs may be appropriate in patients
needing these drugs for (cardiovascular)
comorbidities (14). Since aged patients
more often have comorbidities than
younger patients (31), this may also
explain why being on maximum
treatment was more common in aged
patients.
We can only speculate why potential
undertreatment for HbA1c increased in
the years after the introduction of
performance measures. This finding
could be a temporary effect caused by
changes in the underlying patient
population. The performance measures
were introduced as part of a DM
program that also included a new
payment system. Financial incentives
related to this program may have led to
unintended shifts of patients. Concerns
have been expressed about increasing
numbers of patients with preliminary
stages of diabetes and patients being
moved from specialist to primary care
for financial reasons (32). In contrast,
our finding that this increase was
especially seen in aged patients suggests
that this is not the most likely
explanation. An alternative explanation
would be the intensifying call for using
less strict target levels of ,7.5 (58
mmol/mol) to ,8.5% (69 mmol/mol)
for HbA1c and ,150 mmHg to ,160
mmHg for SBP for aged patients in
recent years (24,33). Our definition of
undertreatment was based on the 2006
guidelines that promoted treatment for
strict target levels in general. Although
these guidelines were changed after
our study period in 2013 (34), it is
likely that norms about less intensive
treatment in aged patients were
already starting to percolate in practice
during the study period (29). Given the
current debate and introduction of
guidelines that recommend less strict
targets in aged patients, future
studies need to apply age-specific
definitions of overtreatment as well
as undertreatment.
In contrast, undertreatment of both BP-
and glucose-lowering treatment was
more common in aged patients than in
younger patients throughout the whole
study period. GPs appear to be more
restrictive in prescribing drugs in aged
patients. A study about the prescription
of b-blockers in patients with coronary
artery disease found a similar result
(35). Several patient-related reasons for
potential undertreatment have been
proposed (36,37), some of which are
likely to differ among age groups. Aged
patients have, for instance, more often
comorbidities (31) and an increased risk
of adverse drug events that may restrict
the therapeutic options, and their
treatment preferences and needs may
also differ from younger patients (38).
Future studies are needed to investigate
the reason behind the difference in
undertreatment among age groups.
Our study does not support the concerns
about increasing overtreatment after the
introduction of performance measures.
Previously, Kerr et al. (14) found an
association between low levels of
undertreatment and high levels of
overtreatment within veterans affairs
facilities. In our study, most
improvements (i.e., reductions) in
undertreatment were observed for BP
treatment. We found that decreases in
undertreatment were significantly
associated with decreases in
overtreatment, which refutes the
hypothesis that GPs felt pressured to
prescribe more treatment in general
after the introduction of performance
measures. This dissimilarity between our
findings and those of Kerr et al. (14) may
be due to differences in the studied
patient population or to slightly different
definitions of over- and undertreatment,
but are more likely due to differences in
the way the performancemeasures have
been implemented (e.g., different
financial incentives) and in the
organization of the healthcare system.
The system that was intended to reduce
undertreatment may have been less
enforced in our country, which is then
expected to result in less aggressive
treatment in general. Indeed, we
observed less overtreatment but also
more undertreatment in our patient
population in comparison with the
population in the study of Kerr et al. (14).
The level of undertreatment in the
years after the implementation of
performance measures, being ;20% of
all patients with a BP measurement and
16% of all patients with an HbA1c
measurement, was much higher than
the level of 6% for BP as seen in the study
of Kerr et al. (14).
Strengths of our study comprise the large
unrestricted cohort of patients with
diabetes and the detailed longitudinal
information on risk factors and drug
prescribing. This allowed us to assess
changes in prescribed treatment relative
to risk factor levels. During the study
period, risk factors were assessed in 84–
94% of the patients. Data were collected
from electronic medical records, and all
included GPs prescribe electronically
using the electronic medical records
system. In the Netherlands, each patient
is registered with a single GP who is the
gatekeeper and obliged to keep adequate
medical records, including out-of-hours
prescriptions made by other
practitioners.
The study is limited by its observational
design and the dynamic cohort
captured. Due to the rolling cohorts,
year 1 covered the period 2009–2011,
whereas year 3 was restricted to 2011
(Fig. 1). Therefore, changes observed in
year 3 can be due to changing norms
over time aswell as sustained or delayed
effects of the program. The findings on
which we base our conclusions,
however, were observed already in the
first year after the introduction of
performance measures and consistent
for all year cohorts. Our outcome
measures have been derived from
guideline recommendations and have
only in part shown associations with
clinical outcomes (Supplemental Table 1)
(39,40). We included the first
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measurement of SBP and HbA1c in a year
and assessed whether the levels of a
follow-up measurement in the 120 days
after the index date returned to control. It
is possible that GPs base the treatment
changes on a longer period. A previous
study showed, however, that an
extended period of 180 days does not
significantly lead to a higher number of
changes after elevated levels (28). Finally,
we only had information about changes
in drug treatment. Therefore, actions
related to nondrug treatment, including
lifestyle and medication adherence, were
not accounted for when assessing
potential undertreatment.
In summary, the introduction of
performance measures reduced
undertreatment for BP, which did not
correspond with an increase in
overtreatment. It seemed that the
performance measures had little impact
on improving glucose-regulating
treatment. There were no clear
differences in trends among different
patient age groups. During the whole
period, undertreatment was higher in
aged patients than in younger patients,
possibly reflecting concerns about the
need for intensive medication
treatment in aged patients.
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